

Title:

Bayesian Network Meta-Analysis of Postoperative Analgesic Techniques in
Thoracoscopic Lung Resection Patients

Authors:

Fang Yue^{1†}, Yongye Xie^{1†}, Xiangdong Chen^{2†}, Ruifen Xu¹, Hui Wang¹, Ning Bai¹,
Minna Hou¹,

† These authors share first authorship, they contributed equally to this work.

Corresponding author:

Jiao Guo^{1,3*}

Affiliations:

¹ Department of Anesthesiology, Shaanxi Provincial People's Hospital, Youyi West
Road No.256, Beilin District, Xi'an, 710000, 029-85251331-3362, China.


² Department of Anesthesiology, Union Hospital, Tongji Medical College, Huazhong
University of Science and Technology

³ Xi'an Medical University, HanGuang North Road No.74, Beilin District, Xi'an,
710000, 029-86177457, China.

E-Mail:

guojane1989@gmail.com (Guo Jia

Supplement 1. Literature Search Process



Supplement 2. Characteristic details of included studies

Characteristic details of 28 included studies

Author Year	Treatment	Total (n)	Gender (M/F)	Age (years)	ASA Class	Block Area	Anesthesia and block timing	Perioperative analgesia strategy	Primary Outcome
Chen G 2019	SAPB	20	11/9	58.9±5.7	I-II	T5-6	SAPB ₁ : preoperation T5-6 (0.4 mL/kg 0.25% ropivacaine)	PCA : sufentanil 0.5 µg/mL and saline at a total volume of 200 mL Rescue analgesia:VAS>4.5, 100 mg tramadol;VAS>5.5, 1mg morphine	pain score(VAS) /sufentanil consumption/postoperative nausea and vomiting (PONV)/additional analgesic requirement/pulmonary complications /time of chest tube removal/length of hospital stay
	Control	20	12/8	57.1±6.2			Control: preoperation single incision- 10 mL 0.25% ropivacaine double-incision - 15 mL(10 mL+5 mL) 0.25% ropivacaine t three - 17 mL(10 mL+5 mL+2 mL) 0.25% ropivacaine		
Chen J 2015	PVB	20	11/9	53±12	I-II	T4-7	PVB ₁ : postoperation T4-7(5ml 0.375% ropivacaine)	PCA : dezocine 0.8 mg/kg+ tropisetron hydrochloride 0.2 mg/kg + normal saline =100 mL	pain score(VAS) /remifentanyl consumption/starting the automatic control button and the total amount of infusion /CEA/ CA199/CA125/NSE/ CYFRA21-1/SCC
	Control	20	12/8	55±11			Control: only general anesthesia		
Chu, H 2020	PVB	25	20/5	58 ± 11	I-III	T4-5/T7-8	PVB ₁ : postoperation T4-5/T7-8(20ml 0.375% ropivacaine)	PCA : sufentanil +ondansetron. Sufentanil 1-2 µg/h. Rescue analgesia:VAS>4,flurbiprofen 50–100 mg.iv	pain scores at rest and on cough/ plasma concentrations of MMP-9/ pneumonia/atelectasis/ air leak/atrial fibrillation/hypotension / PONV
	Control	24	16/8	59 ± 9			Control: only general anesthesia		
Dongjie Q2023	PVB	103	59/44	68±5	I-II	T5	PVB ₁ : preoperation T5(20ml 0.375% ropivacaine)	PCA : dexocine 1mg/kg + ketorolac ambutritol 3mg/kg=100mL Rescue analgesia:VAS>4,flurbiprofen 50 mg / tramadol 100mg.iv	pain score(VAS) /the total amount of opioids/hipoxemia event/operative time/ time of offline extubation/ the occurrence of postoperative delirium/ rescue analgesia,total amount of analgesic drugs/length of hospital stays / postoperative complications (pneumonia or atelectasis within 5 days)
	Control	105	67/38	69±4			Control: only general anesthesia		
Gong C 2023	PVB	135	52/83	59.6 ± 10.7	I-III	T4/T7	PVB ₁ : preoperation T4 、 T7(15ml 0.375% ropivacaine)	Oxycodone 0.1 mg/kg (before the end of surgery) PCA: 1.0 mg fentanyl (20 mL) + saline 80 mL=100ml	pain score(VAS) /(PCA) press count/Intraoperative fentanyl consumption/ postoperative extubation time/PACU stay time/postoperative hospitalization days
	Control	132	39/93	57.3 ± 12.1			Control: only general anesthesia 1% lidocaine 10 mL before closing the incision		
Horth D 2021	continuous ESPB	12	7/5	71.33 ± 9.00	III-IV	T5	ESPB ₁ : continuous ESPB (preoperation) T5 (30 ml 0.125%bupivacaine)	INB ₁ : NRS>4,hydromorphone 0.2–0.4 mg i.v every 7min(maximum :2 mg) PCA:morphine1 to 2 mg i.v. with a lock out time of 7 to 10 min to a maximum of 30 mg over 4h continuous ESPBs: 0.125%bupivacaine at 13 ml /h	total opioid consumption/pain scores “at rest” and “at movement”/nausea-vomiting/respiratory depression/itching/ local anesthetic toxicity/catheter leakage/catheter migration and infection aroundthe catheter site/sensory blockade/Patient satisfaction
	INB	12	10/2	66.50 ± 8.44			INB ₁ : postoperation 0.25% bupivacaine + epinephrine (5 ml per block)		
Kang K 2020	PVB	41	21/20	51.6 ± 11.0	I-III	T4-5/T6-7	PVB ₁ : preoperation T4-5/T6-7(10ml 0.5% ropivacaine each point)	PCA:1 mg/kg oxycodone	GMWT((POD0/POD1/POD2/POD3) / the decline rate of the GMWT on POD1/ the absolute value of walking distance/ pain scores/ oxycodone consumption/sleep quality/ postoperative pulmonary complications/ the hospital stay
	Control	34	16/18	56.1 ± 9.8			Control: only general anesthesia		
Kosiński S 2016	continuous PVB	26	12/14	64.7 ± 7.25	I-III	not mention	continuous PVB : postoperation 20ml 0.25% bupivacaine + adrenaline - 1:200000 0.08-0.1 mL /kg. h	ketoprofen.iv, 100 mg every 12 h; paracetamol iv , 1000 mg every 8 h PCA:morphine 2–2.5 mg every 10 min, a maximum hour dose of 10 mg	pain scores (at rest/ on cough)/ side effects and complications (Atelectasis/Urinary retention)
	continuous TEA	25	10/15	59.9 ± 12.5			continuous TEA: postoperation 6ml 0.25% bupivacaine + adrenaline -1:200000 0.06-0.08 mL/ kg. h		

Lai J 2021	continuous PVB	43	27/16	59 ± 9	I-III	T7-8 <
------------	----------------	----	-------	--------	-------	---

[illegible]

Zhang J-W 2022				54.41 ± 7.61		T4-5	ESPB: preoperation T4-5--30 ml 0.5% ropivacaine	Both: PCA: 100 µg sufentanil+ 25 mg dolasetron mesylate + 0.9% normal saline=100 ml , loading dose 2 ml, background dose 1 ml/h, compression dose 2 ml, lock time 15 min. Rescue analgesia: VAS ≥4 , 50 mg furbiprofen ,iv	pain scores/ intraoperative sufentanil consumption/anesthesia awakening time / extubation time /sufentanil consumption in the analgesic pump /the dose of furbiprofen / nausea and vomiting/agitation/respiratory depression
	ESPB	22	11/11						
	PVB	22	10/12	54.32 ± 6.56	I-II	T4-5	TPVB: preoperation T4-5--30 ml 0.5% ropivacaine		
	Control	23	11/12	52.13 ± 6.55			Control: only general anesthesia		
Zhang X 2015						T4/T7	PVB: postoperation T4,T7--0.5% ropivacaine , maximum 40ml		intraoperative total dose of sufentanil/pain scores/
	PVB	31	20/11	55 ± 9	I-II			40mg parecoxib 0h, 12h and 24 h. PCA:morphine 1mg bolus , lockout time,5-minute	the total amount of morphine used/ dizziness/ pruritus/nausea and vomiting /respiratory depression /satisfaction score
	Control	30	21/9	57 ± 7			Control: postoperation T4,T7--0.5% ropivacaine , maximum 40ml		
Hu LH 2020(中文)						T4-5	PVB: postoperation T4-5--0.375% ropivacaine 20 mL	G--PCA: 1.5µg /kg sufentanil+ 5 mg Tropisetron + 0.9% normal saline=100 ml , loading dose 2 ml, compression dose 0.5 ml, lock time 15 min.	pain scores/The dose and frequency of pethidine /Nausea/ vomiting/ pruritus/lethargy/ respiratory depression/
	PVB	30	16/14	62 ± 10	I-II				The time to resume eating/the rate of active cough/
	Control	30	15/15	62 ± 11			Control: 0.9% physiological saline 20ml	Rescue analgesia: VAS>5,pethidine 50mg, im	the first time to get out of bed/ and the length of hospital stay/
Ding W 2018						T4/T6	PVB: preoperation T4/T6 -- 15 ml of 0.5% ropivacaine	Both: furbiprofen (50 mg every 6 h,iv) TEA : epidural morphine (0.03 mg/kg)	pain scores/the first sufentanil supplement and total dose/required only background infusion of sufentanil/nausea and vomiting/rigors/
	PVB	36	23/13	56.7 ± 9.3			PVB-RD: preoperation T4/T6-- 15ml 0.5%ropivacaine+dexmedetomidine (1 µg/kg)	PCA ---sufentanil (0.01 µg/kg),15 -min lockout , 0.03 µg/kg/h background	hypotension/blood glucose, TNF-α, and IL-6 levels/ increases in catecholamine (A) and cortisol (B) levels/HR (A) and MAP (B)
	PVB-RD	34	12/22	52.7 ± 11.7	I-III	T4/T6		PVB:PCA ---sufentanil (0.01 µg/kg),15 -min lockout , 0.03 µg/kg/h background	
	TEA	32	15/17	53.1 ± 10.9		T5-6	TEA: preoperation T5-6--0.5% ropivacaine,test dose : 2% lidocaine 1:200,000 adrenaline (3.0 ml) 8 ml of 0.5% ropivacaine	PVB-RD:PCA ---sufentanil (0.01 µg/kg),15 -min lockout , 0.03 µg/kg/h background	
	PVB	20		47.1 ± 1.7		T5			ramsay sedation scores/MAP / HR/pain scores/ Analgesic efficacy / postoperative adverse effects
	PVB-RD	20					PVB: preoperation		
Zha J 2021						T5	0.5% ropivacaine 10ml	PCA: 0.02 µg/kg/h sufentanil, 15-min lockout time	
	Control	20		48.1 ± 1.5	I-III		PVB-RD: preoperation 0.5% ropivacaine + 1 µg/kg DEX 10ml		
				45.7 ± 1.3					

Supplement 3.
Bias Risk
Assessment

	Random sequence generation (selection bias)	Allocation concealment (selection bias)	Blinding of participants and personnel (performance bias)	Blinding of outcome assessment (detection bias)	Incomplete outcome data (attrition bias)	Selective reporting (reporting bias)	Other bias
Chen G 2019	+	+	?	?	+	+	+
Chen J 2015	+	?	?	+	+	+	
Chu, H 2020	+	?	?	?	+	+	+
Ding W 2018	?	?	?	+	+	+	+
Dongjie Q2023	+	+	+	+	+	+	+
Gong C 2023	+	+	+	+	+	+	+
Horth D 2021	+	+		+	+	+	
Hu LH 2020	+	?	+	+	+	+	+
Kang K 2020	+	?	+	+	+	+	+
Kosiński S 2016	+	?	+	+	+	+	+
Lai J 2021	+	?		+	+	+	
Lee J 2020	+	+	+	+	+	+	+
Lee J Kim S 2019	+	+	+	+	+	+	+
Orhon Ergun M 2023	+	+	?	+	+	+	+
Qiu L 2021	+	+	?	+	+	+	
Shang LH 2020	+	+	+	+	+	+	+
Shim J-G 2020	+	+	+	+	+	+	+
Sun L 2024	+	+	+	+	+	+	+
Ueda K2020	+	?	?	+	+	+	+
Viti A 2020	+	?	+	+	+	+	+
Wang T 2024	+	+	?	+	+	+	+
Wu W 2023	+	+	+	+	+	+	+
Yang H 2023	+	?	+	+	+		+
Zejun N 2018	+	+		+	+	+	+
Zha J 2021	+	+		+	+	+	?
Zhang J 2023	+	?	?	+	+	+	+
Zhang J-W 2022	+	?	+	+	+	+	+
Zhang X 2015	+	?	+	+	+	+	+

Blinding of participants and personnel (performance bias)

Random sequence generation (selection bias)


Allocation concealment (selection bias)

Blinding of outcome assessment (detection bias)

Incomplete outcome data (attrition bias)

Selective reporting (reporting bias)

Other bias




Low risk of bias


Unclear risk of bias

High risk of bias


Supplement 4. Network Meta- Analysis of Secondary Outcomes




Stacked Rank Plot of Interventions









SAPB	-6.55 (-22.2, 9.32)	2.49 (-10.06, 15.04)	-5.28 (-20.06, 9.73)	-9.01 (-28.85, 11.15)
PVB	9.05 (-0.59, 18.49)	1.27 (-8.27, 10.9)	-2.45 (-14.68, 9.83)	
control		-7.78 (-15.55, 0.27)	-11.5 (-26.94, 4.15)	
		ESPB	-3.7 (-19.28, 11.81)	
			TEA	






Standard Error




d.3.4**d.3.5****d.3.7****d.4.1****sd.d**

Per-arm residual deviance



Leverage versus residual deviance



Supplement 5.
Inconsistency tests and
heterogeneity tests for
primary outcomes

Postoperative 12h Resting VAS

comparison	Node-splitting analysis of inconsistency		p	Heterogeneity
	direct	indirect		I ² (%)
SAPB vs control	NA	NA	NA	98.84
SAPB vs ESPB	-0.09 (-3.63, 3.48)	-2.10 (-5.02, 0.81)	0.34	89.85
SAPB vs INB	NA	NA	NA	NA
PVB vs control	1.23 (-0.65, 3.00)	0.26 (-2.91, 3.52)	0.59	94.52
PVB vs ESPB	0.21 (-2.41, 2.87)	0.70 (-1.94, 3.41)	0.77	0.00
PVB vs TEA	-0.95 (-4.40, 2.42)	0.04 (-3.78, 3.94)	0.68	48.94
control vs ESPB	-0.55 (-2.24, 1.18)	-1.12 (-5.42, 3.19)	0.79	15.83
control vs TEA	-0.99 (-4.53, 2.56)	-2.03 (-5.72, 1.83)	0.68	0.00

Postoperative 12h Coughing VAS

comparison	Node-splitting analysis of inconsistency		p	Heterogeneity
	direct	indirect		I ² (%)
SAPB vs control	NA	NA	NA	92.31
SAPB vs ESPB	0.20 (-1.54, 1.81)	0.83 (-1.13, 2.74)	0.55	0.00
PVB vs control	1.31 (0.39, 2.33)	0.68 (-1.62, 2.96)	0.52	93.89
PVB vs ESPB	0.23 (-1.17, 1.58)	0.72 (-0.93, 2.41)	0.57	69.17
PVB vs TEA	-0.56 (-1.65, 0.55)	-1.4 (-3.61, 0.77)	0.39	NA
control vs ESPB	NA	NA	NA	0.00

Postoperative 24h Resting VAS

comparison	Node-splitting analysis of inconsistency		p	Heterogeneity
	direct	indirect		I ² (%)
SAPB vs control	-0.12 (-1.27, 0.88)	0.10 (-2.73, 2.96)	0.87	95.32
SAPB vs ESPB	-0.53 (-2.72, 1.73)	-0.80 (-2.25, 0.53)	0.81	0.00
SAPB vs INB	-0.01 (-2.22, 2.18)	-0.23 (-2.18, 1.67)	0.86	94.53
PVB vs control	1.03 (0.29, 1.82)	0.87 (-0.81, 2.63)	0.85	90.43
PVB vs ESPB	0.07 (-1.51, 1.65)	0.53 (-0.76, 1.87)	0.64	16.17
PVB vs TEA	0.04 (-1.51, 1.64)	-0.01 (-1.62, 1.61)	0.96	91.68
control vs ESPB	-0.51 (-1.62, 0.61)	-0.90 (-2.76, 0.88)	0.69	68.42
control vs TEA	-1.13 (-2.76, 0.45)	-0.90 (-2.45, 0.60)	0.82	87.15
ESPB vs INB	0.62 (-1.16, 2.47)	0.55 (-1.42, 2.67)	0.96	0.00
INB vs TEA	-0.67 (-3.38, 1.92)	-1.1 (-3.35, 0.75)	0.79	0.00


Postoperative 24h Coughing VAS

comparison	Node-splitting analysis of inconsistency		p	Heterogeneity
	direct	indirect		I ² (%)
SAPB vs control	NA	NA	NA	75.25
SAPB vs ESPB	-0.75 (-2.53, 0.98)	-0.19 (-1.61, 1.28)	0.59	55.29
PVB vs control	0.88 (0.09, 1.72)	1.3 (-0.35, 3.00)	0.63	93.66
PVB vs ESPB	0.02 (-1.20, 1.21)	0.88 (-0.48, 2.22)	0.31	82.84
PVB vs TEA	0.70 (-0.53, 1.92)	-0.90 (-2.7, 0.93)	0.14	71.72

control vs ESPB	-0.05 (-1.03, 0.90)	-1.2 (-3.03, 0.59)	0.23	87.11
control vs TEA	-1.72(-3.47, -0.02)	-0.11 (-1.52, 1.31)	0.14	90.03
ESPB vs INB	NA	NA	NA	92.87
Postoperative 48h Resting VAS				
	Node-splitting analysis of inconsistency			Heterogeneity
comparison	direct	indirect	p	I²(%)
SAPB vs control	NA	NA	NA	94.08
PVB vs control	0.55 (0.06, 1.05)	0.85 (-0.11, 1.85)	0.55	84.38
PVB vs ESPB	0.026 (-0.77, 0.82)	0.44 (-0.44, 1.26)	0.44	97.46
PVB vs TEA	0.14 (-0.56, 0.85)	-0.69 (-1.54, 0.24)	0.15	88.34
control vs ESPB	-0.10 (-0.73, 0.53)	-0.92 (-2.67, 0.05)	0.15	93.36
control vs TEA	-1.52 (-2.28, -0.71)	-0.29 (-0.94, 0.41)	0.02	94.99
ESPB vs INB	0.55 (-0.35, 1.63)	-0.59 (-2.43, 1.28)	0.26	55.84
INB vs TEA	-0.01 (-1.62, 1.63)	-1.1 (-2.47, 0.06)	0.26	53.65
Postoperative 48h Coughing VAS				
	Node-splitting analysis of inconsistency			Heterogeneity
comparison	direct	indirect	p	I²(%)
SAPB vs control	NA	NA	NA	97.59
PVB vs control	0.59 (-0.48, 1.62)	1.8 (-0.18, 3.87)	0.25	96.18
PVB vs ESPB	0.04 (-1.55, 1.63)	0.69 (-1.86, 3.24)	0.62	99.13
PVB vs TEA	0.76 (-0.41, 2.00)	-1.52 (-3.47, 0.30)	0.04	92.82
control vs ESPB	-0.24 (-1.80, 1.34)	-1.18 (-3.64, 1.42)	0.51	81.81
control vs TEA	-2.1 (-3.81, -0.41)	0.20 (-1.25, 1.76)	0.04	96.49
ESPB vs INB	NA	NA	NA	94.03
Nausea and Vomiting				
	Node-splitting analysis of inconsistency			Heterogeneity
comparison	direct	indirect	p	I²(%)
SAPB vs control	NA	NA	NA	45.51
SAPB vs ESPB	0.34 (-2.13, 2.87)	-1.35 (-3.14, 0.59)	0.28	44.15
PVB vs control	0.79 (-0.08, 1.75)	2.09 (-0.07, 3.95)	0.26	64.22
PVB vs ESPB	-0.62 (-2.62, 1.34)	-0.08 (-1.62, 1.67)	0.66	0.00
PVB vs TEA	1.40 (0.03, 2.93)	-0.88 (-2.62, 1.14)	0.06	77.14
control vs ESPB	-1.14 (-2.34, 0.20)	-2.23 (-4.93, 0.35)	0.43	45.05
control vs TEA	-2.23 (-4.27, -0.36)	0.65 (-0.76, 2.15)	0.02	92.35
ESPB vs INB	0.99 (-0.97, 3.18)	-0.20 (-4.54, 3.57)	0.57	0.00
INB vs TEA	0.92 (-2.49, 4.93)	-0.29 (-3.25, 2.3)	0.567	0.00
Pulmonary Complications				
	Node-splitting analysis of inconsistency			Heterogeneity
comparison	direct	indirect	p	I²(%)
SAPB vs control	NA	NA	NA	0.00
SAPB vs ESPB	NA	NA	NA	NA
PVB vs control	0.37 (-0.50, 1.33)	6.25 (-9.24, 28.03)	0.49	0.01
PVB vs TEA	0.22 (-1.34, 1.83)	-2.54 (-23.03, 15.50)	0.71	0.00
control vs ESPB	NA	NA	NA	NA







control vs TEA	-5.1 (-23., 11.00)	-0.14 (-1.9, 1.7)	0.53	0
Hospital Stay				
	Node-splitting analysis of inconsistency			Heterogeneity
comparison	direct	indirect	p	I²(%)
SAPB vs control	NA	NA	NA	4.29
PVB vs control	1.12 (-0.24, 2.4)	-0.33 (-2.6, 2.00)	0.26	95.05
PVB vs ESPB	-1.41 (-4.56, 1.23)	0.31 (-2.16, 2.7)	0.30	55.53
PVB vs TEA	-0.41 (-3.22, 2.36)	0.27 (-2.87, 2.46)	0.68	0.00
control vs ESPB	-0.69 (-3.13, 1.78)	-1.92 (-4.44, 0.71)	0.45	52.05
control vs TEA	-0.44 (-2.31, 1.52)	-1.41 (-4.06, 1.31)	0.54	0.00
ESPB vs INB	-0.80 (-3.73, 2.28)	0.24 (-4.42, 4.97)	0.70	0.00
INB vs TEA	0.42 (-3.62, 4.45)	1.52 (-2.37, 5.25)	0.69	0.00






Supplement 6. Publication bias















1: SAPB; 3: PVB; 4: control; 5: ESPB; 6: INB; 7: TEA







Supplement 7. Model Fitting Performance of all Primary Outcomes







d.1.4**d.1.5****d.1.6****d.4.3****d.4.7****sd.d****Postoperative 12h Resting VAS**







d.3.4**d.3.5****d.3.7****d.4.1****sd.d****Postoperative 12h Coughing VAS**

d.1.4**d.1.5****d.1.6****d.4.3****d.4.7****sd.d****Postoperative 24h Resting VAS**






d.3.4**d.3.5****d.3.7****d.5.1****d.5.6****sd.d****Postoperative 24h Coughing VAS**







d.4.1**d.4.3****d.4.5****d.4.7****d.5.6****sd.d****Postoperative 48h Resting VAS**

d.4.1**d.4.3****d.4.5****d.4.7****d.5.6****sd.d****Postoperative 48h Coughing VAS**


d.3.4**d.3.5****d.3.7****d.5.1****d.5.6****sd.d**

Postoperative Nausea and Vomiting


d.4.1**d.4.3****d.4.5****d.4.7****sd.d****Pulmonary Complications**

d.4.1**d.4.3****d.4.5****d.4.7****d.5.6****sd.d****Length of Hospital Stay**


Trace of d.4.3




Density of d.4.3




Trace of d.4.5




Density of d.4.5



Trace of sd.d




Density of sd.d




Postoperative 12h Resting VAS


Trace of d.4.1




Density of d.4.1



Trace of sd.d




Density of sd.d




Postoperative 12h Coughing VAS


Trace of d.4.3




Density of d.4.3




Trace of d.4.7




Density of d.4.7



Trace of sd.d




Density of sd.d




Postoperative 24h Resting VAS


Trace of d.5.1




Density of d.5.1




Trace of d.5.6




Density of d.5.6



Trace of sd.d




Density of sd.d




Postoperative 24h Coughing VAS


Trace of d.4.7




Density of d.4.7




Trace of d.5.6




Density of d.5.6



Trace of sd.d




Density of sd.d




Postoperative 48h Resting VAS


Trace of d.4.7




Density of d.4.7




Trace of d.5.6




Density of d.5.6



Trace of sd.d




Density of sd.d




Postoperative 48h Coughing VAS


Trace of d.5.1




Density of d.5.1




Trace of d.5.6




Density of d.5.6



Trace of sd.d




Density of sd.d




Postoperative Nausea and Vomiting


Trace of d.4.7




Density of d.4.7




Trace of sd.d




Density of sd.d




Trace of d.4.7




Density of d.4.7




Trace of d.5.6




Density of d.5.6



Trace of sd.d




Density of sd.d




Length of Hospital Stay


Per-arm residual deviance




Leverage versus residual deviance



Per-arm residual deviance




Leverage versus residual deviance




Postoperative 12h Coughing VAS


Per-arm residual deviance




Leverage versus residual deviance



Per-arm residual deviance




Leverage versus residual deviance




Postoperative 24h Coughing VAS

Per-arm residual deviance




Leverage versus residual deviance




Square root of residual deviance

Postoperative 48h Resting VAS

Per-arm residual deviance




Leverage versus residual deviance




Postoperative 48h Coughing VAS

Per-arm residual deviance




Leverage versus residual deviance




Postoperative Nausea and Vomiting

Per-arm residual deviance




Leverage versus residual deviance




Pulmonary Complications


Per-arm residual deviance




Leverage versus residual deviance




**Supplement 8. Network Meta-
Analysis and Comparison
Following the Exclusion of
Clinical Trials Without PCA
Implementation**




Postoperative 12h Resting VAS




Postoperative 12h Coughing VAS




Postoperative 24h Resting VAS




Postoperative 24h Coughing VAS




Postoperative 48h Resting VAS




Postoperative 48h Coughing VAS



Postoperative Nausea and Vomiting



Pulmonary Complications



Length of Hospital Stay

Postoperative 12h Resting VAS			Postoperative 24h Resting VAS			Postoperative 48h Resting VAS		
11 trails, 926 patients, PSRF=1			17 trails, 1404 patients, PSRF=1.01			11 trails, 1029 patients, PSRF=1		
Rank	Treatment	SUCRA	Rank	Treatment	SUCRA	Rank	Treatment	SUCRA
1	TEA	0.865	1	PVB	0.864	1	PVB	0.881
2	PVB	0.732	2	TEA	0.729	2	TEA	0.685
3	ESPB	0.604	3	ESPB	0.642	3	ESPB	0.48
4	PCA	0.478	4	PCA	0.424	4	SAPB	0.237
5	INB	0.193	5	INB	0.211	5	PCA	0.217
6	SAPB	0.129	6	SAPB	0.129			


Postoperative 12h Coughing VAS			Postoperative 24h Coughing VAS			Postoperative 48h Coughing VAS		
6 trails, 673 patients, PSRF=1			10 trails, 1033 patients, PSRF=1			7 trails, 795 patients, PSRF=1		
Rank	Treatment	SUCRA	Rank	Treatment	SUCRA	Rank	Treatment	SUCRA
1	TEA	0.994	1	PVB	0.905	1	PVB	0.781
2	PVB	0.679	2	ESPB	0.618	2	ESPB	0.71
3	SAPB	0.441	3	PCA	0.415	3	PCA	0.442
4	ESPB	0.365	4	TEA	0.383	4	SAPB	0.367
5	PCA	0.02	5	SAPB	0.179	5	TEA	0.2

Postoperative Nausea and Vomiting			Pulmonary Complications			Length of Hospital Stay		
15 trails, 1318 patients, PSRF=1			7 trails, 646 patients, PSRF=1			6 trails, 587 patients, PSRF=1		
Rank	Treatment	SUCRA	Rank	Treatment	SUCRA	Rank	Treatment	SUCRA
1	ESPB	0.942	1	PVB	0.694	1	SAPB	0.618
2	SAPB	0.625	2	ESPB	0.657	2	PVB	0.557
3	PVB	0.609	3	TEA	0.514	3	ESPB	0.539
4	PCA	0.287	4	PCA	0.442	4	TEA	0.521
5	TEA	0.037	5	SAPB	0.192	5	PCA	0.263

Postoperative 12h Resting VAS					
SAPB	-2.38 (-4.94, 0.21)	-1.68 (-3.75, 0.39)	-1.96 (-4.2, 0.28)	0 (-3.09, 3.08)	-3.03 (-6.16, 0.11)
PVB		0.7 (-0.9, 2.29)	0.42 (-1.51, 2.34)	2.38 (-1.64, 6.37)	-0.64 (-3.03, 1.73)
		PCA	-0.28 (-1.6, 1.05)	1.68 (-2.04, 5.39)	-1.35 (-3.72, 1.04)
			ESPB	1.96 (-1.85, 5.78)	-1.06 (-3.72, 1.62)
				INB	-3.03 (-7.41, 1.37)
				TEA	
Postoperative 24h Resting VAS					
SAPB	-1.79 (-3.28, -0.39)	-0.93 (-2.23, 0.27)	-1.33 (-2.87, 0.11)	0 (-2.19, 2.2)	-1.58 (-3.49, 0.25)
PVB		0.86 (0.11, 1.61)	0.46 (-0.76, 1.69)	1.79 (-0.78, 4.48)	0.21 (-1.11, 1.56)
		PCA	-0.4 (-1.44, 0.65)	0.93 (-1.54, 3.52)	-0.65 (-2.04, 0.77)
			ESPB	1.33 (-1.26, 4.04)	-0.24 (-1.97, 1.49)
				INB	-1.58 (-4.5, 1.26)
				TEA	
Postoperative 48h Resting VAS					
SAPB	-0.51 (-1.28, 0.27)	-0.05 (-0.75, 0.65)	-0.21 (-1.03, 0.61)	-0.39 (-1.27, 0.52)	
PVB		0.46 (0.14, 0.77)	0.3 (-0.19, 0.78)	0.12 (-0.38, 0.62)	
		PCA	-0.16 (-0.57, 0.25)	-0.33 (-0.89, 0.23)	
			ESPB	-0.17 (-0.85, 0.5)	
				TEA	
Postoperative 12h Coughing VAS					
SAPB	-0.29 (-1.36, 0.6)	0.64 (-0.23, 1.48)	0.08 (-0.77, 0.93)	-1.79 (-3.31, -0.43)	
PVB		0.92 (0.47, 1.53)	0.36 (-0.21, 1.11)	-1.5 (-2.56, -0.43)	
		PCA	-0.56 (-1.08, -0.02)	-2.42 (-3.67, -1.3)	
			ESPB	-1.87 (-3.18, -0.68)	
				TEA	
Postoperative 24h Coughing VAS					
SAPB	-0.99 (-2.26, 0.21)	-0.38 (-1.45, 0.64)	-0.61 (-1.8, 0.55)	-0.3 (-2.01, 1.39)	
PVB		0.61 (-0.07, 1.3)	0.38 (-0.6, 1.39)	0.7 (-0.48, 1.88)	
		PCA	-0.22 (-1.05, 0.61)	0.09 (-1.27, 1.44)	
			ESPB	0.31 (-1.22, 1.84)	
				TEA	
Postoperative 48h Coughing VAS					
SAPB	-0.44 (-2.01, 1.16)	-0.13 (-1.5, 1.26)	-0.4 (-2.06, 1.3)	0.21 (-1.54, 2.27)	
PVB		0.31 (-0.49, 1.09)	0.05 (-1.03, 1.12)	0.67 (-0.26, 1.84)	
		PCA	-0.27 (-1.2, 0.69)	0.35 (-0.83, 1.8)	
			ESPB	0.61 (-0.76, 2.24)	
				TEA	
Postoperative Nausea and Vomiting					
SAPB	1.07 (0.32, 3.34)	1.66 (0.65, 4.22)	0.49 (0.16, 1.78)	4.27 (0.78, 23.71)	

	PVB	1.54 (0.78, 3.38)	0.46 (0.17, 1.58)	3.96 (1.23, 14.67)
	PCA		0.3 (0.13, 0.77)	2.57 (0.61, 10.99)
			ESPB	8.67 (1.53, 41.18)
			TEA	
Length of Hospital Stay				
SAPB	0.31 (-3.27, 3.97)	1 (-2.13, 4.11)	0.31 (-3.99, 4.54)	0.38 (-3.56, 4.33)
	PVB	0.69 (-1.22, 2.5)	-0.01 (-3.52, 3.4)	0.06 (-2.39, 2.47)
	PCA		-0.7 (-3.6, 2.22)	-0.62 (-3.04, 1.82)
			ESPB	0.08 (-3.68, 3.9)
			TEA	

Stacked Rank Plot of Interventions
(Postoperative 12h Resting VAS)



Stacked Rank Plot of Interventions
(Postoperative 12h Coughing VAS)

Proportion

1.00
0.75
0.50
0.25
0.00

SAPB

PVB

PCA

ESPB

TEA

Intervention

Rank


Rank5

Rank4


Rank3

Rank2

Rank1



Stacked Rank Plot of Interventions
(Postoperative 24h Resting VAS)



Stacked Rank Plot of Interventions
(Postoperative 24h Coughing VAS)

Proportion

1.00
0.75
0.50
0.25
0.00

Rank

Rank5
Rank4
Rank3
Rank2
Rank1

SAPB


PVB

PCA

ESPB

TEA

Intervention



Stacked Rank Plot of Interventions
(Postoperative 48h Resting VAS)

Proportion

1.00
0.75
0.50
0.25
0.00

SAPB

PVB

PCA


ESPB

TEA


Intervention

Rank

Rank5
Rank4
Rank3
Rank2
Rank1



Stacked Rank Plot of Interventions
(Postoperative 48h Coughing VAS)



Stacked Rank Plot of Interventions
(Postoperative Nausea and Vomiting)

Proportion

1.00
0.75
0.50
0.25
0.00

SAPB

PVB

PCA

ESPB

TEA

Intervention

Rank


Rank5

Rank4

Rank3

Rank2

Rank1



Stacked Rank Plot of Interventions
(Pulmonary Complications)

Proportion

1.00
0.75
0.50
0.25
0.00

SAPB

PVB

PCA


ESPB

TEA

Intervention

Rank

Rank5
Rank4
Rank3
Rank2
Rank1



Stacked Rank Plot of Interventions
(Length of Hospital Stay)

Proportion

1.00
0.75
0.50
0.25
0.00

SAPB

PVB

PCA


ESPB


TEA

Intervention


Rank

Rank5
Rank4
Rank3
Rank2
Rank1







Inconsistency tests for Postoperative 12h Resting VAS
(1: SAPB; 3: PVB; 4: control; 5: ESPB; 6: INB; 7: TEA)




Inconsistency tests for Postoperative 12h Coughing VAS
(1: SAPB; 3: PVB; 4: control; 5: ESPB; 6: INB; 7: TEA)




Inconsistency tests for Postoperative 24h Resting VAS
(1: SAPB; 3: PVB; 4: control; 5: ESPB; 6: INB; 7: TEA)




Inconsistency tests for Postoperative 24h Coughing VAS
(1: SAPB; 3: PVB; 4: control; 5: ESPB; 6: INB; 7: TEA)




Inconsistency tests for Postoperative 48h Resting VAS
(1: SAPB; 3: PVB; 4: control; 5: ESPB; 6: INB; 7: TEA)



Inconsistency tests for Postoperative 48h Coughing VAS
(1: SAPB; 3: PVB; 4: control; 5: ESPB; 6: INB; 7: TEA)




Inconsistency tests for Postoperative Nausea and Vomiting
(1: SAPB; 3: PVB; 4: control; 5: ESPB; 6: INB; 7: TEA)




Inconsistency tests for Length of Hospital Stay


(1: SAPB; 3: PVB; 4: control; 5: ESPB; 6: INB; 7: TEA)




heterogeneity tests for Postoperative 12h Resting VAS
(1: SAPB; 3: PVB; 4: control; 5: ESPB; 6: INB; 7: TEA)




heterogeneity tests for Postoperative 12h Coughing VAS
(1: SAPB; 3: PVB; 4: control; 5: ESPB; 6: INB; 7: TEA)




heterogeneity tests for Postoperative 24h Resting VAS
(1: SAPB; 3: PVB; 4: control; 5: ESPB; 6: INB; 7: TEA)




heterogeneity tests for Postoperative 24h Coughing VAS
(1: SAPB; 3: PVB; 4: control; 5: ESPB; 6: INB; 7: TEA)




heterogeneity tests for Postoperative 48h Resting VAS
(1: SAPB; 3: PVB; 4: control; 5: ESPB; 6: INB; 7: TEA)




heterogeneity tests for Postoperative 48h Coughing VAS
(1: SAPB; 3: PVB; 4: control; 5: ESPB; 6: INB; 7: TEA)



heterogeneity tests for Postoperative Nausea and Vomiting
(1: SAPB; 3: PVB; 4: control; 5: ESPB; 6: INB; 7: TEA)




heterogeneity tests for Pulmonary Complications
(1: SAPB; 3: PVB; 4: control; 5: ESPB; 6: INB; 7: TEA)




heterogeneity tests for Length of Hospital Stay
(1: SAPB; 3: PVB; 4: control; 5: ESPB; 6: INB; 7: TEA)


**Supplement 9. Network Meta-
Analysis and Comparison
Following the Exclusion of
High-Risk Clinical Trials**




Postoperative 12h Resting VAS




Postoperative 12h Coughing VAS




Postoperative 24h Resting VAS




Postoperative 24h Coughing VAS




Postoperative 48h Resting VAS




Postoperative 48h Coughing VAS



Postoperative Nausea and Vomiting



Pulmonary Complications




Length of Hospital Stay

Postoperative 12h Resting VAS			Postoperative 24h Resting VAS			Postoperative 48h Resting VAS		
11 trails, 954 patients, PSRF=1			19 trails, 1601 patients, PSRF=1			15 trails, 1308 patients, PSRF=1		
Rank	Treatment	SUCRA	Rank	Treatment	SUCRA	Rank	Treatment	SUCRA
1	TEA	0.918	1	PVB	0.871	1	PVB	0.853
2	PVB	0.722	2	TEA	0.685	2	TEA	0.608
3	ESPB	0.465	3	ESPB	0.631	3	SAPB	0.547
4	INB	0.403	4	SAPB	0.439	4	ESPB	0.54
5	SAPB	0.388	5	INB	0.291	5	INB	0.294
6	control	0.102	6	control	0.083	6	control	0.158
Postoperative 12h Coughing VAS			Postoperative 24h Coughing VAS			Postoperative 48h Coughing VAS		
7 trails, 743 patients, PSRF=1			13 trails, 1269 patients, PSRF=1			11 trails, 1071 patients, PSRF=1		
Rank	Treatment	SUCRA	Rank	Treatment	SUCRA	Rank	Treatment	SUCRA
1	TEA	0.967	1	PVB	0.912	1	PVB	0.761
2	PVB	0.656	2	ESPB	0.649	2	SAPB	0.725
3	SAPB	0.417	3	TEA	0.486	3	ESPB	0.641
4	ESPB	0.408	4	SAPB	0.34	4	control	0.34
5	control	0.052	5	INB	0.306	5	TEA	0.288
			6	control	0.307	6	INB	0.244
Postoperative Nausea and Vomiting			Pulmonary Complications			Length of Hospital Stay		
15 trails, 1339 patients, PSRF=1			6 trails, 526 patients, PSRF=1			10 trails, 820 patients, PSRF=1		
Rank	Treatment	SUCRA	Rank	Treatment	SUCRA	Rank	Treatment	SUCRA
1	ESPB	0.861	1	TEA	0.773	1	INB	0.745
2	SAPB	0.694	2	ESPB	0.585	2	ESPB	0.672
3	PVB	0.678	3	PVB	0.575	3	PVB	0.543
4	INB	0.349	4	control	0.394	4	SAPB	0.442
5	control	0.308	5	SAPB	0.172	5	TEA	0.411
6	TEA	0.11				6	control	0.186

Postoperative 12h Resting VAS					
SAPB	-0.59 (-1.92, 0.78)	0.47 (-0.77, 1.71)	-0.16 (-1.39, 1.07)	0 (-1.31, 1.32)	-1.14 (-2.75, 0.55)
PVB	1.06 (0.41, 1.67)	0.43 (-0.3, 1.11)	0.59 (-1.31, 2.46)		-0.55 (-1.61, 0.55)
	control	-0.63 (-1.17, -0.09)	-0.47 (-2.28, 1.34)		-1.61 (-2.68, -0.46)
		ESPB	0.16 (-1.64, 1.97)		-0.98 (-2.12, 0.25)
		INB			-1.14 (-3.22, 1.01)
					TEA
Postoperative 24h Resting VAS					
SAPB	-0.54 (-1.35, 0.31)	0.46 (-0.24, 1.19)	-0.24 (-1.03, 0.58)	0.19 (-0.74, 1.17)	-0.33 (-1.37, 0.74)
PVB	1 (0.52, 1.47)	0.3 (-0.36, 0.95)	0.74 (-0.28, 1.74)		0.2 (-0.6, 1.02)
	control	-0.7 (-1.28, -0.13)	-0.26 (-1.23, 0.69)		-0.79 (-1.63, 0.05)
		ESPB	0.44 (-0.5, 1.38)		-0.09 (-1.04, 0.87)
		INB			-0.53 (-1.66, 0.61)
					TEA
Postoperative 48h Resting VAS					
SAPB	-0.23 (-0.92, 0.53)	0.29 (-0.3, 0.97)	0.01 (-0.72, 0.81)	0.24 (-0.77, 1.28)	-0.06 (-0.88, 0.85)
PVB	0.53 (0.18, 0.87)	0.24 (-0.2, 0.68)	0.47 (-0.35, 1.25)		0.17 (-0.36, 0.72)
	control	-0.28 (-0.71, 0.13)	-0.06 (-0.87, 0.72)		-0.35 (-0.94, 0.25)
		ESPB	0.23 (-0.52, 0.93)		-0.07 (-0.71, 0.59)
		INB			-0.29 (-1.13, 0.58)
					TEA
Postoperative 12h Coughing VAS					
SAPB	-0.45 (-2.17, 1.26)	0.72 (-0.85, 2.28)	0 (-1.57, 1.56)	-1.95 (-4.44, 0.54)	
PVB	1.17 (0.28, 2.06)	0.44 (-0.54, 1.45)		-1.5 (-3.3, 0.3)	
	control	-0.72 (-1.63, 0.19)	-2.66 (-4.67, -0.65)		
		ESPB	-1.94 (-4, 0.1)		
			TEA		
Postoperative 24h Coughing VAS					
SAPB	-0.96 (-2.16, 0.25)	0.01 (-0.97, 1.02)	-0.48 (-1.67, 0.71)	0.16 (-1.92, 2.25)	-0.25 (-2.02, 1.53)
PVB	0.97 (0.24, 1.71)	0.48 (-0.46, 1.42)	1.12 (-0.85, 3.09)		0.71 (-0.6, 2.02)
	control	-0.49 (-1.36, 0.36)	0.15 (-1.78, 2.06)		-0.26 (-1.77, 1.23)
		ESPB	0.64 (-1.08, 2.35)		0.23 (-1.38, 1.84)
		INB			-0.42 (-2.76, 1.95)
					TEA
Postoperative 48h Coughing VAS					
SAPB	0.03 (-1.42, 1.61)	0.6 (-0.61, 1.94)	0.2 (-1.38, 1.91)	0.99 (-1.33, 3.44)	0.8 (-1.1, 2.88)
PVB	0.57 (-0.25, 1.39)	0.16 (-0.87, 1.2)	0.96 (-1.04, 2.98)		0.77 (-0.49, 2.09)
	control	-0.41 (-1.44, 0.64)	0.39 (-1.61, 2.41)		0.2 (-1.29, 1.75)
		ESPB	0.8 (-0.93, 2.53)		0.61 (-1.02, 2.29)
		INB			-0.19 (-2.54, 2.22)
					TEA

Postoperative Nausea and Vomiting					
SAPB	1.08 (0.21, 5.37)	2.38 (0.62, 9.29)	0.69 (0.15, 3.49)	2.96 (0.17, 64.62)	7.21 (0.51, 120.63)
PVB		2.21 (0.89, 5.81)	0.64 (0.21, 2.28)	2.76 (0.21, 45.43)	6.68 (0.77, 73.95)
		control	0.29 (0.11, 0.83)	1.24 (0.09, 20.38)	3.02 (0.3, 36.8)
			ESPB	4.25 (0.35, 64.45)	10.49 (0.94, 125.75)
				INB	2.38 (0.18, 36.97)
					TEA
Pulmonary Complications					
SAPB	0.42 (0.06, 2.62)	0.6 (0.14, 2.46)	0.41 (0.07, 2.1)	0.17 (0, 4.68)	
PVB		1.4 (0.44, 4.75)	0.97 (0.11, 8.25)	0.4 (0.01, 6.34)	
		control	0.69 (0.1, 4)	0.28 (0.01, 5.61)	
			ESPB	0.41 (0.01, 13.72)	
				TEA	
Length of Hospital Stay					
SAPB	-0.27 (-2.58, 2.18)	0.56 (-1.35, 2.53)	-0.67 (-3.34, 2.08)	-1.08 (-4.59, 2.51)	0.07 (-3.16, 3.29)
PVB		0.84 (-0.59, 2.17)	-0.4 (-2.42, 1.55)	-0.81 (-3.9, 2.27)	0.34 (-2.56, 3.11)
		control	-1.23 (-3.12, 0.69)	-1.65 (-4.58, 1.35)	-0.49 (-3.07, 2.05)
			ESPB	-0.42 (-3.07, 2.29)	0.74 (-2.19, 3.61)
				INB	1.15 (-1.96, 4.2)
					TEA

Stacked Rank Plot of Interventions
(Postoperative 12h Resting VAS)



Stacked Rank Plot of Interventions
(Postoperative 12h Coughing VAS)

Proportion

1.00
0.75
0.50
0.25
0.00

Rank

Rank5
Rank4
Rank3
Rank2
Rank1

SAPB


PVB

control


ESPB

TEA


Intervention




Stacked Rank Plot of Interventions
(Postoperative 24h Resting VAS)




Stacked Rank Plot of Interventions
(Postoperative 24h Coughing VAS)




Stacked Rank Plot of Interventions
(Postoperative 48h Resting VAS)




Stacked Rank Plot of Interventions
(Postoperative 48h Coughing VAS)




**Stacked Rank Plot of Interventions
(Postoperative Nausea and Vomiting)**




Stacked Rank Plot of Interventions
(Pulmonary Complications)




Stacked Rank Plot of Interventions
(Length of Hospital Stay)







Inconsistency tests for Postoperative 12h Resting VAS
 (1: SAPB; 3: PVB; 4: control; 5: ESPB; 6: INB; 7: TEA)




Inconsistency tests for Postoperative 12h Coughing VAS
(1: SAPB; 3: PVB; 4: control; 5: ESPB; 6: INB; 7: TEA)




Inconsistency tests for Postoperative 24h Resting VAS
(1: SAPB; 3: PVB; 4: control; 5: ESPB; 6: INB; 7: TEA)




Inconsistency tests for Postoperative 24h Coughing VAS
(1: SAPB; 3: PVB; 4: control; 5: ESPB; 6: INB; 7: TEA)




Inconsistency tests for Postoperative 48h Resting VAS
(1: SAPB; 3: PVB; 4: control; 5: ESPB; 6: INB; 7: TEA)




Inconsistency tests for Postoperative 48h Coughing VAS
(1: SAPB; 3: PVB; 4: control; 5: ESPB; 6: INB; 7: TEA)




Inconsistency tests for Postoperative Nausea and Vomiting
 (1: SAPB; 3: PVB; 4: control; 5: ESPB; 6: INB; 7: TEA)




Inconsistency tests for Length of Hospital Stay
(1: SAPB; 3: PVB; 4: control; 5: ESPB; 6: INB; 7: TEA)




heterogeneity tests for Postoperative 12h Resting VAS
(1: SAPB; 3: PVB; 4: control; 5: ESPB; 6: INB; 7: TEA)




heterogeneity tests for Postoperative 12h Coughing VAS
(1: SAPB; 3: PVB; 4: control; 5: ESPB; 6: INB; 7: TEA)




heterogeneity tests for Postoperative 24h Resting VAS
(1: SAPB; 3: PVB; 4: control; 5: ESPB; 6: INB; 7: TEA)



heterogeneity tests for Postoperative 24h Coughing VAS
(1: SAPB; 3: PVB; 4: control; 5: ESPB; 6: INB; 7: TEA)




heterogeneity tests for Postoperative 48h Resting VAS
(1: SAPB; 3: PVB; 4: control; 5: ESPB; 6: INB; 7: TEA)




heterogeneity tests for Postoperative 48h Coughing VAS


(1: SAPB; 3: PVB; 4: control; 5: ESPB; 6: INB; 7: TEA)



heterogeneity tests for Postoperative Nausea and Vomiting
(1: SAPB; 3: PVB; 4: control; 5: ESPB; 6: INB; 7: TEA)




heterogeneity tests for Pulmonary Complications
(1: SAPB; 3: PVB; 4: control; 5: ESPB; 6: INB; 7: TEA)




heterogeneity tests for Length of Hospital Stay

(1: SAPB; 3: PVB; 4: control; 5: ESPB; 6: INB; 7: TEA)


**Supplement 10. Network Meta-
Analysis and Comparison
Following the Exclusion of
Postoperative Continuous
Catheter-Based Nerve Blocks**




Postoperative 12h Resting VAS




Postoperative 12h Coughing VAS




Postoperative 24h Resting VAS




Postoperative 24h Coughing VAS




Postoperative 48h Resting VAS




Postoperative 48h Coughing VAS



Postoperative Nausea and Vomiting



Pulmonary Complications



Length of Hospital Stay

Table:

Postoperative 12h Resting VAS			Postoperative 24h Resting VAS			Postoperative 48h Resting VAS		
13 trails, 1058 patients, PSRF=1			21 trails, 1694 patients, PSRF=1.01			15 trails, 1319 patients, PSRF=1		
Rank	Treatment	SUCRA	Rank	Treatment	SUCRA	Rank	Treatment	SUCRA
1	TEA	0.823	1	PVB	0.816	1	PVB	0.84
2	PVB	0.749	2	TEA	0.783	2	TEA	0.744
3	ESPB	0.562	3	ESPB	0.605	3	SAPB	0.519
4	control	0.381	4	INB	0.315	4	ESPB	0.469
5	INB	0.289	5	control	0.262	5	INB	0.258
6	SAPB	0.196	6	SAPB	0.219	6	control	0.169


Postoperative 12h Coughing VAS			Postoperative 24h Coughing VAS			Postoperative 48h Coughing VAS		
8 trails, 805 patients, PSRF=1			13 trails, 1280 patients, PSRF=1			10 trails, 1042 patients, PSRF=1		
Rank	Treatment	SUCRA	Rank	Treatment	SUCRA	Rank	Treatment	SUCRA
1	TEA	0.971	1	PVB	0.856	1	PVB	0.738
2	PVB	0.641	2	TEA	0.606	2	TEA	0.616
3	SAPB	0.546	3	ESPB	0.572	3	ESPB	0.573
4	ESPB	0.321	4	SAPB	0.38	4	SAPB	0.568
5	control	0.021	5	control	0.317	5	control	0.301
			6	INB	0.268	6	INB	0.203

Postoperative Nausea and Vomiting			Length of Hospital Stay		
17 trails, 1411 patients, PSRF=1			9 trails, 770 patients, PSRF=1		
Rank	Treatment	SUCRA	Rank	Treatment	SUCRA
1	ESPB	0.872	1	PVB	0.694
2	PVB	0.735	2	INB	0.662
3	SAPB	0.593	3	SAPB	0.495
4	INB	0.356	4	ESPB	0.487
5	control	0.329	5	TEA	0.416
6	TEA	0.115	6	control	0.246

Postoperative 12h Resting VAS					
SAPB	-1.75 (-4.18, 0.67)	-0.72 (-2.64, 1.16)	-1.15 (-3.38, 1.03)	0 (-3.43, 3.42)	-2.24 (-5.44, 0.96)
PVB		1.03 (-0.53, 2.59)	0.59 (-1.39, 2.59)	1.75 (-2.42, 5.96)	-0.49 (-3.07, 2.08)
		control	-0.43 (-1.89, 1.01)	0.72 (-3.17, 4.65)	-1.52 (-4.12, 1.06)
			ESPB	1.15 (-2.9, 5.25)	-1.09 (-4, 1.83)
				INB	-2.24 (-6.92, 2.42)
					TEA
Postoperative 24h Resting VAS					
SAPB	-1.06 (-2.25, 0.08)	-0.11 (-1.08, 0.83)	-0.65 (-1.91, 0.56)	-0.13 (-1.68, 1.39)	-1.1 (-2.79, 0.59)
PVB		0.95 (0.23, 1.67)	0.41 (-0.76, 1.57)	0.94 (-0.69, 2.56)	-0.04 (-1.54, 1.48)
		control	-0.54 (-1.54, 0.45)	-0.02 (-1.55, 1.52)	-0.99 (-2.46, 0.5)
			ESPB	0.53 (-1.01, 2.07)	-0.45 (-2.14, 1.26)
				INB	-0.97 (-2.76, 0.84)
					TEA
Postoperative 48h Resting VAS					
SAPB	-0.27 (-0.81, 0.33)	0.25 (-0.2, 0.76)	0.04 (-0.57, 0.7)	0.25 (-0.66, 1.13)	-0.23 (-0.99, 0.63)
PVB		0.52 (0.2, 0.83)	0.31 (-0.18, 0.79)	0.52 (-0.31, 1.26)	0.04 (-0.57, 0.7)
		control	-0.21 (-0.64, 0.21)	0 (-0.8, 0.73)	-0.48 (-1.11, 0.2)
			ESPB	0.2 (-0.51, 0.86)	-0.27 (-0.98, 0.49)
				INB	-0.47 (-1.29, 0.45)
					TEA
Postoperative 12h Coughing VAS					
SAPB	-0.19 (-1.53, 1.13)	1.13 (0.02, 2.22)	0.42 (-0.81, 1.67)	-1.69 (-3.87, 0.47)	
PVB		1.31 (0.52, 2.11)	0.61 (-0.46, 1.71)	-1.5 (-3.21, 0.21)	
		control	-0.7 (-1.58, 0.19)	-2.81 (-4.7, -0.94)	
			ESPB	-2.11 (-4.15, -0.1)	
				TEA	
Postoperative 24h Coughing VAS					
SAPB	-0.81 (-1.95, 0.35)	0.06 (-0.84, 0.97)	-0.29 (-1.49, 0.92)	0.35 (-1.79, 2.51)	-0.46 (-2.66, 1.76)
PVB		0.87 (0.13, 1.61)	0.52 (-0.61, 1.65)	1.16 (-0.97, 3.27)	0.35 (-1.54, 2.25)
		control	-0.35 (-1.32, 0.62)	0.29 (-1.75, 2.33)	-0.52 (-2.55, 1.51)
			ESPB	0.64 (-1.15, 2.43)	-0.17 (-2.39, 2.05)
				INB	-0.81 (-3.64, 2.03)
					TEA
Postoperative 48h Coughing VAS					
SAPB	-0.25 (-1.53, 1.14)	0.34 (-0.63, 1.42)	0 (-1.49, 1.6)	0.8 (-1.46, 3.17)	-0.15 (-2.29, 2.11)
PVB		0.59 (-0.26, 1.44)	0.25 (-1.03, 1.54)	1.05 (-1.11, 3.2)	0.1 (-1.64, 1.85)
		control	-0.35 (-1.5, 0.82)	0.45 (-1.62, 2.53)	-0.49 (-2.43, 1.46)
			ESPB	0.8 (-0.93, 2.52)	-0.15 (-2.33, 2.03)
				INB	-0.95 (-3.72, 1.84)
					TEA
Postoperative Nausea and Vomiting					

SAPB	0.75 (0.18, 3.07)	1.66 (0.54, 5.27)	0.53 (0.13, 2.35)	2.18 (0.14, 43.12)	5.13 (0.43, 74.85)
PVB		2.21 (0.97, 5.3)	0.7 (0.21, 2.65)	2.89 (0.23, 48.4)	6.75 (0.83, 72.67)
		control	0.32 (0.12, 0.93)	1.3 (0.1, 21.4)	3.05 (0.33, 35.64)
			ESPB	4.06 (0.34, 62.51)	9.63 (0.91, 115.69)
				INB	2.3 (0.17, 34.2)
					TEA
Length of Hospital Stay					
SAPB	-0.53 (-2.9, 1.96)	0.56 (-1.34, 2.51)	-0.01 (-3, 3.08)	-0.6 (-4.19, 3.1)	0.22 (-2.99, 3.44)
PVB		1.09 (-0.42, 2.54)	0.51 (-2.28, 3.3)	-0.07 (-3.49, 3.38)	0.74 (-2.25, 3.68)
		control	-0.57 (-2.91, 1.81)	-1.15 (-4.24, 1.98)	-0.34 (-2.91, 2.23)
			ESPB	-0.59 (-3.25, 2.11)	0.23 (-2.85, 3.27)
				INB	0.81 (-2.34, 3.9)
					TEA

Stacked Rank Plot of Interventions
(Postoperative 12h Resting VAS)



Stacked Rank Plot of Interventions
(Postoperative 12h Coughing VAS)

Proportion

1.00
0.75
0.50
0.25
0.00

Rank

Rank5
Rank4
Rank3
Rank2
Rank1

SAPB


PVB

control


ESPB

TEA


Intervention




Stacked Rank Plot of Interventions
(Postoperative 24h Resting VAS)




Stacked Rank Plot of Interventions
(Postoperative 24h Coughing VAS)




Stacked Rank Plot of Interventions
(Postoperative 48h Resting VAS)




Stacked Rank Plot of Interventions
(Postoperative 48h Coughing VAS)




Stacked Rank Plot of Interventions
(Postoperative Nausea and Vomiting)




Stacked Rank Plot of Interventions
(Length of Hospital Stay)







inconsistency tests for Postoperative 12h Resting VAS
(1: SAPB; 3: PVB; 4: control; 5: ESPB; 6: INB; 7: TEA)




inconsistency tests for Postoperative 12h Coughing VAS
(1: SAPB; 3: PVB; 4: control; 5: ESPB; 6: INB; 7: TEA)




inconsistency tests for Postoperative 24h Resting VAS
(1: SAPB; 3: PVB; 4: control; 5: ESPB; 6: INB; 7: TEA)




inconsistency tests for Postoperative 24h Coughing VAS
(1: SAPB; 3: PVB; 4: control; 5: ESPB; 6: INB; 7: TEA)



inconsistency tests for Postoperative 48h Resting VAS
(1: SAPB; 3: PVB; 4: control; 5: ESPB; 6: INB; 7: TEA)




inconsistency tests for Postoperative 48h Coughing VAS
(1: SAPB; 3: PVB; 4: control; 5: ESPB; 6: INB; 7: TEA)




inconsistency tests for Postoperative Nausea and Vomiting

(1: SAPB; 3: PVB; 4: control; 5: ESPB; 6: INB; 7: TEA)




inconsistency tests for Length of Hospital Stay


(1: SAPB; 3: PVB; 4: control; 5: ESPB; 6: INB; 7: TEA)




heterogeneity tests for Postoperative 12h Resting VAS
(1: SAPB; 3: PVB; 4: control; 5: ESPB; 6: INB; 7: TEA)




heterogeneity tests for Postoperative 12h Coughing VAS
(1: SAPB; 3: PVB; 4: control; 5: ESPB; 6: INB; 7: TEA)




heterogeneity tests for Postoperative 24h Resting VAS
 (1: SAPB; 3: PVB; 4: control; 5: ESPB; 6: INB; 7: TEA)




heterogeneity tests for Postoperative 24h Coughing VAS
(1: SAPB; 3: PVB; 4: control; 5: ESPB; 6: INB; 7: TEA)




heterogeneity tests for Postoperative 48h Resting VAS
(1: SAPB; 3: PVB; 4: control; 5: ESPB; 6: INB; 7: TEA)



heterogeneity tests for Postoperative 48h Coughing VAS
(1: SAPB; 3: PVB; 4: control; 5: ESPB; 6: INB; 7: TEA)



heterogeneity tests for Postoperative Nausea and Vomiting
(1: SAPB; 3: PVB; 4: control; 5: ESPB; 6: INB; 7: TEA)




heterogeneity tests for Length of Hospital Stay
(1: SAPB; 3: PVB; 4: control; 5: ESPB; 6: INB; 7: TEA)

**Supplement 11. Meta
Regression Analyses—The
Impact of LA on the Outcomes**


d.4.1

Treatment effect vs. covariate




d.4.3

Treatment effect vs. covariate




d.4.5

Treatment effect vs. covariate




d.4.6

Treatment effect vs. covariate




d.4.7

Treatment effect vs. covariate




Influence of local anesthetic infiltration (LA) on postoperative 24h resting VAS
 (1: SAPB; 3: PVB; 4: control; 5: ESPB; 6: INB; 7: TEA)


Treatment effect vs. covariate




Treatment effect vs. covariate



Treatment effect vs. covariate




Treatment effect vs. covariate



Influence of local anesthetic infiltration (LA) on postoperative 24h coughing VAS
(1: SAPB; 3: PVB; 4: control; 5: ESPB; 6: INB; 7: TEA)


d.4.1

Treatment effect vs. covariate




d.4.3

Treatment effect vs. covariate




d.4.5

Treatment effect vs. covariate




d.4.6

Treatment effect vs. covariate




d.4.7

Treatment effect vs. covariate




Influence of local anesthetic infiltration (LA) on postoperative 48h resting VAS
 (1: SAPB; 3: PVB; 4: control; 5: ESPB; 6: INB; 7: TEA)


Treatment effect vs. covariate




Treatment effect vs. covariate



Treatment effect vs. covariate




Treatment effect vs. covariate




Influence of local anesthetic infiltration (LA) on postoperative 48h coughing VAS
(1: SAPB; 3: PVB; 4: control; 5: ESPB; 6: INB; 7: TEA)

Treatment effect vs. covariate




Treatment effect vs. covariate




Treatment effect vs. covariate




Treatment effect vs. covariate



Treatment effect vs. covariate




Treatment effect vs. covariate




Influence of local anesthetic infiltration (LA) on postoperative nausea and vomiting
(1: SAPB; 3: PVB; 4: control; 5: ESPB; 6: INB; 7: TEA)


Treatment effect vs. covariate




Treatment effect vs. covariate




Treatment effect vs. covariate



Treatment effect vs. covariate




Treatment effect vs. covariate




Influence of local anesthetic infiltration (LA) on pulmonary complications
(1: SAPB; 3: PVB; 4: control; 5: ESPB; 6: INB; 7: TEA)


Treatment effect vs. covariate




Treatment effect vs. covariate




Treatment effect vs. covariate



Treatment effect vs. covariate




Treatment effect vs. covariate




Influence of local anesthetic infiltration (LA) on length of hospital stay
 (1: SAPB; 3: PVB; 4: control; 5: ESPB; 6: INB; 7: TEA)

**Supplement 12. Meta
Regression Analyses—The
Impact of High-Risk Literature
on the Outcomes**


Treatment effect vs. covariate




Treatment effect vs. covariate




Treatment effect vs. covariate



Treatment effect vs. covariate




Treatment effect vs. covariate




Influence of risk of bias on postoperative 12h resting VAS
(1: SAPB; 3: PVB; 4: control; 5: ESPB; 6: INB; 7: TEA)


Treatment effect vs. covariate




Treatment effect vs. covariate



Treatment effect vs. covariate




Treatment effect vs. covariate




Influence of risk of bias on postoperative 12h coughing VAS
(1: SAPB; 3: PVB; 4: control; 5: ESPB; 6: INB; 7: TEA)


Treatment effect vs. covariate




Treatment effect vs. covariate




Treatment effect vs. covariate



Treatment effect vs. covariate




Treatment effect vs. covariate




Influence of risk of bias on postoperative 24h resting VAS
(1: SAPB; 3: PVB; 4: control; 5: ESPB; 6: INB; 7: TEA)


Treatment effect vs. covariate




Treatment effect vs. covariate




Treatment effect vs. covariate



Treatment effect vs. covariate




Treatment effect vs. covariate




Influence of risk of bias on postoperative 24h coughing VAS
(1: SAPB; 3: PVB; 4: control; 5: ESPB; 6: INB; 7: TEA)


Treatment effect vs. covariate




Treatment effect vs. covariate




Treatment effect vs. covariate



Treatment effect vs. covariate




Treatment effect vs. covariate




Influence of risk of bias on postoperative 48h resting VAS
(1: SAPB; 3: PVB; 4: control; 5: ESPB; 6: INB; 7: TEA)


Treatment effect vs. covariate




Treatment effect vs. covariate




Treatment effect vs. covariate



Treatment effect vs. covariate




Treatment effect vs. covariate




Influence of risk of bias on postoperative 48h coughing VAS
(1: SAPB; 3: PVB; 4: control; 5: ESPB; 6: INB; 7: TEA)


Treatment effect vs. covariate




Treatment effect vs. covariate




Treatment effect vs. covariate




Treatment effect vs. covariate



Treatment effect vs. covariate




Treatment effect vs. covariate




Influence of risk of bias on postoperative nausea and vomiting
 (1: SAPB; 3: PVB; 4: control; 5: ESPB; 6: INB; 7: TEA)


Treatment effect vs. covariate




Treatment effect vs. covariate




Treatment effect vs. covariate



Treatment effect vs. covariate




Treatment effect vs. covariate




Influence of risk of bias on pulmonary complications
(1: SAPB; 3: PVB; 4: control; 5: ESPB; 6: INB; 7: TEA)


Treatment effect vs. covariate




Treatment effect vs. covariate




Treatment effect vs. covariate



Treatment effect vs. covariate



Treatment effect vs. covariate



Influence of risk of bias on length of hospital stay
(1: SAPB; 3: PVB; 4: control; 5: ESPB; 6: INB; 7: TEA)